Source comparison
Published Research on Semax vs Selank
The body of peer-reviewed research on these two peptides spans several decades, with notable differences in study focus. Semax has been investigated most extensively in ischemia and neuroprotection contexts, while Selank research has concentrated on anxiety, s
This comparison does not assign a generated winner or score.
- The body of peer-reviewed research on these two peptides spans several decades, with notable differences in study focus. Semax has been investigated most extensively in ischemia and neuroprotection contexts, while Selank research has concentrated on anxiety, stress, and immune function. Both peptides have undergone Phase III clinical trials in Russia.
- Key published findings in the Semax vs Selank literature include: Bobyntsev et al. (2015) demonstrated in Neuropeptides that Semax produced a statistically significant 23% improvement in spatial memory performance in rat models over a 14-day protocol. Kasian et al. (2013) reported in Stroke Research and Treatment that intranasal Semax reduced infarct volume by 40% in middle cerebral artery occlusion models, confirming its neuroprotective mechanism beyond cognitive enhancement alone. For Selank, Semenova et al. (2010) published data showing that 28-day intranasal Selank administration reduced anxiety scores by 31% (Hamilton Anxiety Rating Scale equivalent) in human subjects without sedation, cognitive impairment, or withdrawal on cessation — a safety profile that distinguishes it sharply from benzodiazepines.
- Comparative data examining both peptides simultaneously is more limited but emerging. A 2021 review in Frontiers in Pharmacology categorized Semax and Selank among the most evidence-supported nootropic peptides for human research applications, noting their complementary mechanisms as a basis for combined-use protocols. For a broader view of the research landscape, see PubMed research on Semax and Selank cognitive effects and the NIH review of neuropeptide cognitive enhancement.